CMS’ decision to allow Medicare Part D plan sponsors to switch biosimilars into their formularies at any time throughout the plan year without permission from the agency may have a negative impact of patient cost-sharing unless states are able to secure pharmacists the ability to do the same, American Society of Health-System Pharmacists (ASHP) Vice President of Government Relations Tom Krauss told Inside Drug Pricing . The pharmacist lobby is planning to form model legislative language that states could use...